Physician profile
Amy U Dave
NPI 1104929363
$1,555.21
in general payments reported to CMS, 2019-2025
16 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $361 · 2023: $138 · 2024: $118 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.81 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $330.98 | 2022-2025 | Tezspire, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $307.68 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $172.53 | 2021 | |
| Celgene Corporation | $125.76 | 2021-2023 | Reblozyl |
| Janssen Biotech, INC. | $99.99 | 2021 | |
| Amgen INC. | $82.80 | 2021-2022 | |
| Corcept Therapeutics | $78.36 | 2025 | Korlym |
| Abbott Laboratories | $71.16 | 2025 | Eterna |
| Pharmacyclics LLC, An Abbvie Company | $69.82 | 2021 | |
| Genzyme Corporation | $67.09 | 2025 | |
| Abbvie INC. | $55.88 | 2022-2025 | |
| Taiho Oncology, INC. | $22.43 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.53 | 2021 | |
| Mirati Therapeutics, INC. | $20.36 | 2023 | Krazati |
| Lilly USA, LLC | $16.88 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.